Acorda Therapeutics (NASDAQ:ACOR) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a note issued to investors on Monday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

The company has a quick ratio of 0.26, a current ratio of 0.33 and a debt-to-equity ratio of 3.07. The company has a market cap of $820,000.00, a PE ratio of 0.00 and a beta of 1.40. The business has a fifty day simple moving average of $10.27 and a 200 day simple moving average of $11.87. Acorda Therapeutics has a one year low of $0.61 and a one year high of $24.20.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.